Guggenheim Capital LLC Decreases Holdings in Edwards Lifesciences Co. (NYSE:EW)

Guggenheim Capital LLC reduced its position in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 6.7% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 215,406 shares of the medical research company's stock after selling 15,358 shares during the quarter. Guggenheim Capital LLC's holdings in Edwards Lifesciences were worth $15,947,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. Harbor Capital Advisors Inc. increased its stake in Edwards Lifesciences by 2.5% during the fourth quarter. Harbor Capital Advisors Inc. now owns 11,135 shares of the medical research company's stock worth $824,000 after acquiring an additional 273 shares during the last quarter. Nordea Investment Management AB increased its stake in Edwards Lifesciences by 34.6% in the 4th quarter. Nordea Investment Management AB now owns 4,057,013 shares of the medical research company's stock worth $301,355,000 after buying an additional 1,043,484 shares during the period. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST raised its stake in shares of Edwards Lifesciences by 6.7% during the fourth quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST now owns 4,800,000 shares of the medical research company's stock valued at $355,344,000 after acquiring an additional 300,000 shares in the last quarter. Sivik Global Healthcare LLC purchased a new stake in shares of Edwards Lifesciences in the 4th quarter worth $3,702,000. Finally, Avanza Fonder AB bought a new position in Edwards Lifesciences during the 4th quarter worth about $4,845,000. Institutional investors own 79.46% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the company. Morgan Stanley increased their target price on Edwards Lifesciences from $70.00 to $75.00 and gave the company an "equal weight" rating in a research report on Wednesday, February 12th. Stifel Nicolaus upgraded shares of Edwards Lifesciences from a "hold" rating to a "buy" rating and lifted their target price for the company from $75.00 to $90.00 in a research report on Thursday, January 30th. Evercore ISI reduced their price target on shares of Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating for the company in a research report on Wednesday, February 12th. Barclays lifted their price objective on Edwards Lifesciences from $88.00 to $90.00 and gave the stock an "overweight" rating in a report on Thursday, February 13th. Finally, Royal Bank of Canada reissued an "outperform" rating and set a $85.00 target price on shares of Edwards Lifesciences in a report on Wednesday, February 12th. One research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $78.55.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, CEO Bernard J. Zovighian sold 6,164 shares of the company's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $69.51, for a total transaction of $428,459.64. Following the sale, the chief executive officer now owns 59,083 shares in the company, valued at $4,106,859.33. This represents a 9.45 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Scott B. Ullem sold 11,250 shares of Edwards Lifesciences stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $75.76, for a total value of $852,300.00. Following the completion of the transaction, the chief financial officer now owns 30,561 shares of the company's stock, valued at $2,315,301.36. The trade was a 26.91 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 71,853 shares of company stock worth $5,163,062. 1.29% of the stock is currently owned by company insiders.

Edwards Lifesciences Trading Up 0.5 %

EW traded up $0.36 on Friday, hitting $71.56. The company had a trading volume of 3,235,636 shares, compared to its average volume of 4,927,071. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The firm has a market cap of $42.07 billion, a P/E ratio of 10.27, a PEG ratio of 4.82 and a beta of 1.15. The company's fifty day moving average price is $71.31 and its 200 day moving average price is $70.85. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $95.25.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, topping analysts' consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. As a group, equities analysts expect that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.